DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xz4r6z/herpes_simplex) has announced the addition of the "Herpes simplex Partnering 2009-2014" report to their offering.

The Herpes Simplex Partnering 2009-2014 provides understanding and access to the herpes simplex partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of herpes simplex partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors herpes simplex technology. These deals tend to be multi-component, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report includes:

• Trends in herpes simplex dealmaking in the biopharma industry since 2009
• Access to summary headline, upfront, milestone and royalty data
• The leading herpes simplex deals by value since 2009

In Herpes Simplex Partnering 2009-2014, the available deals are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Company A-Z
• Industry sector
• Stage of development at signing
• Deal component type
• Technology type

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in herpes simplex partnering

Chapter 3 - Leading herpes simplex deals

Chapter 4 - Dealmaking directory

Chapter 5 - Partnering resource center

For more information visit http://www.researchandmarkets.com/research/xz4r6z/herpes_simplex